Lonza bone marrow and cord blood mononuclear cells

Monday, 18 April, 2011 | Supplied by: Capsugel Australia Pty Ltd

Lonza’s bone marrow and cord blood mononuclear cells are prepared by centrifugation in a density cell separation medium (Ficoll-Paque, Amersham Pharmacia).

Isolating the mononuclear cells eliminates erythrocytes and granulocytes, producing a more stable cell product.

Mononuclear cells can be used directly in hematopoietic assays or as the starting material for isolating CD34+ progenitor cells.

Cells are available cryopreserved with varying numbers or cells per ampule, starting from >25 million cells.

Online: www.capsugel.com
Phone: 1300 657508

Content from other channels on our network

Fine Food Sydney cancelled

Proper mussel cooking recommended following infections

Canning experts discuss hygienic machine design

An anti-competitive environment is impacting the supply chain

Food testing quality assurance program opens

Fluence, ReNew announce JV to boost energy storage in India

Circular battery economy: challenges and future approaches to recycling

Solar cells get thinner, tougher and more efficient

WaterStart pilot intelligent water system solution

From carbon dioxide to solid carbon using RMIT technology

2022 Thought Leaders: Jon McGettigan

Registrations now open for AUSPACK 2022

FANUC introduces robot with 1-tonne payload

Australia sending first shipment of hydrogen to Japan

Digitalisation in pulp and paper to exceed US$3.6 billion: report

Lonza bone marrow and cord blood mononuclear cells

Cayman Chemical Cell Death Screening Library

GeneTex circadian rhythm antibodies

Enzo Life Sciences SCREEN-WELL Cardiotoxicity Library

Content from other channels on our network